Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6805860

Title:Method of transluminal application of myogenic cells for repair or replacement of heart tissue
Inventors:Alt, Eckhard; D-85521 Ottobrunn, Germany
Summary:This invention introduces a method of repairing myocardial tissue in a patient's body, via the delivery of preferably autologous adult stem cells by intraluminal application through a blood vessel, with temporary occlusion of the vessel to increase stem cell concentration. The invention relates to the cellular repair of failing tissue of an organ in a patient's body, by which a catheter is positioned to provide an entry point for stem cell injection at the proximal end of the central lumen of the catheter external to the body and an exit point from the central lumen at the distal end proximate the site of the failing tissue. Further described are methods by which the stem cells are then injected through the catheter to invade the failing tissue at the site, while local forces at the site are quelled from disrupting migration of the stem cells into the failing tissue, to enhance the concentration of the stem cells and the pressure arising from the injection at the site and thereby overcome any barrier between the site of the injection and the failing tissue.
Abstract:A process is described for cellular repair of failing tissue of an organ if a patient's body. In the process, a catheter is positioned to provide an entry point for stem cell injection at the proximal end of the central lumen of the catheter external to the body and an exit point from the central lumen at the distal end proximate the site of the failing tissue. Stem cells are then injected through the catheter to invade the failing tissue at the site, while local forces at the site are quelled from disrupting migration of the stem cells into the failing tissue, to enhance the concentration of the stem cells and the pressure arising from the injection at the site and thereby overcome any barrier between the site of the injection and the failing tissue. Preferably, autologous adult stem cells are used in the procedure.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6805860
Application Number:US2001000968739
Date Filed:30/09/2001
Date Published:19/10/2004
Assignee:None


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021